Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.62 |
| ▸ | TNNI3K | Q59H18 | 7/20 | 0.62 |
| ▸ | BRAF | P15056 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4244096 | 0.89 | L3MBTL1 (0.57) | KDRMAPK14TNNI3KBRAFMAPT | |
| SCHEMBL12825474 | 0.85 | KDR (0.62) | KDRMAPK14TNNI3KBRAFMAPT | |
| SCHEMBL7780979 | 0.84 | ALDH1A1 (0.52) | KDRMAPK14TNNI3KBRAFMAPT | |
| SCHEMBL7783065 | 0.82 | ALDH1A1 (0.54) | KDRMAPK14TNNI3KBRAFMAPT | |
| SCHEMBL17772777 | 0.82 | MAPT (0.61) | KDRMAPK14TNNI3KBRAFMAPT | |
| SCHEMBL8773803 | 0.81 | ALDH1A1 (0.53) | KDRMAPK14TNNI3KBRAFMAPT | |
| SCHEMBL7775883 | 0.81 | MAPT (0.48) | KDRMAPK14TNNI3KBRAFMAPT | |
| Hydrochloric Acid SCHEMBL7776436 | 0.81 | MAPT (0.48) | KDRMAPK14TNNI3KBRAFMAPT | |
| SCHEMBL17720569 | 0.80 | MAP4K4 (0.52) | KDRMAPK14TNNI3KBRAFMAPT | |
| SCHEMBL17623901 | 0.79 | ALDH1A1 (0.53) | MAPTALDH1A1POLBL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9271501-B2 | Use of strobilurin type compounds for combating phytopathogenic fungi resistant to QO inhibitors | BASF SE (DE) | 2016-03-01 | — | — | US | disclosed |
| US-20140323305-A1 | Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors | BASF SE (DE) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323305-A1 | Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors | SQOR, COX5B, UQCRB | KDR 4492/4885MAPK14 3910/4885TNNI3K 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.